Johnson & Johnson (JNJ) stock
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3083% above fair value
$272.70−6.00 (-2.15%)
Close on Nov 18, 2026Market cap $656.47BP/E 41.4Yield 1.88%
Johnson & Johnson operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2014 it was $21.59B, up 31.6% from the year before. The highest annual figure on record is $21.59B in fiscal 2014.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2014 | Dec 28, 2014 | $21.59B | +31.6% |
| FY2013 | Dec 29, 2013 | $16.41B | +9.7% |
| FY2012 | Dec 30, 2012 | $14.96B | +8.6% |
| FY2011 | Jan 1, 2012 | $13.77B | -22.2% |
| FY2010 | Jan 2, 2011 | $17.70B | +6.7% |
| FY2009 | Jan 3, 2010 | $16.58B | – |
See a number that looks wrong?